Osteoarthritis Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Osteoarthritis Pain - Pipeline Review, H2 2016

Osteoarthritis Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Osteoarthritis Pain - Pipeline Review, H2 2016
Published Oct 29, 2016
212 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain Pipeline Review, H2 2016, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 19, 6, 1, 17, 5 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Osteoarthritis Pain.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule

  
Source:
Document ID
GMDHC8600IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents211
  List of Tables102
  List of Figures121
Introduction131
  Global Markets Direct Report Coverage131
Osteoarthritis Pain Overview141
Therapeutics Development152
  Pipeline Products for Osteoarthritis Pain Overview151
  Pipeline Products for Osteoarthritis Pain Comparative Analysis161
Osteoarthritis Pain Therapeutics under Development by Companies173
Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes201
Osteoarthritis Pain Pipeline Products Glance214
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
  Unknown Stage Products241
Osteoarthritis Pain Products under Development by Companies254
Osteoarthritis Pain Products under Investigation by Universities/Institutes291
Osteoarthritis Pain Companies Involved in Therapeutics Development3039
  AbbVie Inc301
  Addex Therapeutics Ltd311
  Afferent Pharmaceuticals, Inc.321
  Akron Molecules AG331
  Allergan Plc341
  Ampio Pharmaceuticals, Inc.351
  Antibe Therapeutics, Inc.361
  Aralez Pharmaceuticals Inc.371
  Arena Pharmaceuticals, Inc.381
  Array BioPharma Inc.391
  AskAt Inc.401
  Astellas Pharma Inc.411
  Axsome Therapeutics Inc421
  Biogen Inc431
  Boehringer Ingelheim GmbH441
  Cara Therapeutics, Inc.451
  Centrexion Therapeutics Corp461
  Chromocell Corporation471
  Eli Lilly and Company481
  Elite Pharmaceuticals, Inc.491
  Eupraxia Pharmaceuticals Inc.501
  Flexion Therapeutics, Inc.511
  Genzyme Corporation521
  GlaxoSmithKline Plc531
  Glenmark Pharmaceuticals Ltd.541
  Grunenthal GmbH551
  Iroko Pharmaceuticals, LLC561
  Medestea Research &Production S.p.A.571
  MedImmune, LLC581
  Nuvo Pharmaceuticals Inc.591
  Pfizer Inc.601
  Phosphagenics Limited611
  pSivida Corp.621
  Purdue Pharma LP631
  Regeneron Pharmaceuticals Inc641
  Symic Biomedical, Inc.651
  Taiwan Liposome Company, Ltd.661
  Vertex Pharmaceuticals Incorporated671
  Zynerba Pharmaceuticals Inc681
Osteoarthritis Pain Therapeutics Assessment6915
  Assessment by Monotherapy Products691
  Assessment by Combination Products701
  Assessment by Target714
  Assessment by Mechanism of Action755
  Assessment by Route of Administration802
  Assessment by Molecule Type822
Drug Profiles84110
  (amlodipine besylate + celecoxib) Drug Profile843
  (lidocaine + tetracaine) Drug Profile872
  (naltrexone hydrochloride + oxycodone hydrochloride) SR Drug Profile891
  2-CCPA Drug Profile901
  AAT-008 Drug Profile911
  adefovir dipivoxil Drug Profile921
  ADX-71441 Drug Profile933
  AF-219 Drug Profile964
  Ampion Drug Profile1008
  Antisense Oligonucleotide to Block SCN9A for Erythromelalgia, Neuropathic Pain, Osteoarthritis Pain and Rheumatoid Arthritis Pain Drug Profile1081
  APD-371 Drug Profile1091
  AQU-010 Drug Profile1101
  ARRY-954 Drug Profile1111
  AS-288640100 Drug Profile1121
  ASP-7962 Drug Profile1131
  ATB-346 Drug Profile1144
  AXIBU-01 Drug Profile1181
  BI-1026706 Drug Profile1191
  capsaicin Drug Profile1202
  CC-8464 Drug Profile1222
  cebranopadol Drug Profile1243
  celecoxib Drug Profile1271
  CR-4056 Drug Profile1281
  CRB-0089 Drug Profile1291
  dapansutrile Drug Profile1301
  difelikefalin Drug Profile1318
  duloxetine hydrochloride DR Drug Profile1392
  ELS-130 Drug Profile1411
  fasinumab Drug Profile1423
  fluticasone propionate ER Drug Profile1451
  GRC-27864 Drug Profile1461
  GSK-3196165 Drug Profile1473
  GZ-389988 Drug Profile1501
  ibuprofen Drug Profile1511
  MED-1101 Drug Profile1521
  MEDI-7352 Drug Profile1531
  naproxen sodium Drug Profile1541
  NEO-5937 Drug Profile1551
  NEO-6860 Drug Profile1561
  onabotulinumtoxin A Drug Profile1575
  oxycodone ER Drug Profile1623
  PA-300 DR Drug Profile1651
  PA-65020 Drug Profile1661
  SB-061 Drug Profile1671
  Small Molecule for Osteoarthritis Pain Drug Profile1681
  Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain Drug Profile1691
  Small Molecules for Osteoarthritis Pain Drug Profile1701
  Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain Drug Profile1711
  Small Molecules to Block Nav1.7 for Osteoarthritis Pain Drug Profile1721
  Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain Drug Profile1731
  Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation Drug Profile1741
  Small Molecules to Inhibit PDE2 for Osteoarthritis Pain Drug Profile1751
  tanezumab Drug Profile1763
  TLC-599 Drug Profile1792
  triamcinolone acetonide sodium phosphate SR Drug Profile1815
  VG-201 Drug Profile1861
  VM-902A Drug Profile1871
  VX-150 Drug Profile1881
  zoledronic acid Drug Profile1892
  ZYN-002 Drug Profile1913
Osteoarthritis Pain Dormant Projects1945
Osteoarthritis Pain Discontinued Products1992
Osteoarthritis Pain Product Development Milestones20110
  Featured News &Press Releases2011
    Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs2011
    Sep 27, 2016: Kitov Reports Successful Results for Additional KIT-302 Pharmacokinetic Bioequivalence Study2021
    Sep 15, 2016: Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients2021
    Sep 14, 2016: Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors2031
    Sep 12, 2016: Flexion Therapeutics Announces Two Key Corporate Appointments2031
    Sep 06, 2016: Kitov Pharmaceuticals to Present Data From a U.S. Market Assessment for KIT-3022041
    Aug 10, 2016: Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA2051
    Aug 03, 2016: Ampio Updates Regulatory Status of AMPION2051
    Jul 06, 2016: Flexion Therapeutics Adds Three New Executives in Key Roles to Support the Planned Commercial Launch of Zilretta2061
    Jun 30, 2016: Ampio announces results of Ampion trials2071
    Jun 28, 2016: Kitov Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA2071
    Jun 24, 2016: Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function2081
    May 30, 2016: Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference2091
    May 27, 2016: Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S.2091
    May 26, 2016: Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta for Osteoarthritis of the Knee2101
Appendix2112
  Methodology2111
  Coverage2111
  Secondary Research2111
  Primary Research2111
  Expert Panel Validation2111
  Contact Us2111
  Disclaimer2121

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Osteoarthritis Pain - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteoarthritis-Pain-Pipeline-Review-H2-2016-2088-16716>
  
APA:
Global Markets Direct - Market Research. (2016). Osteoarthritis Pain - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Osteoarthritis-Pain-Pipeline-Review-H2-2016-2088-16716>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.